Sanofi-GSK COVID booster outperforms Pfizer/BioNTech vaccine against Omicron (NASDAQ: SNY)

Sanofi (NASDAQ:SNY) (OTCPK: SNYNF) said Monday that an upgraded version of the COVID-19 vaccine the company is developing with GSK (GSK) works better than Pfizer (PFE) / BioNTech (BNTX) vaccine as a booster shot against the Omicron variant.

The 247-subject study was designed to evaluate the efficacy of the next-generation recombinant and recombinant vaccine candidates Sanofi-GSK and the third dose of Pfizer (PFE) / BioNTech (BNTX) vaccine in individuals who initially received two doses of the mRNA-based vaccine.

All three vaccines produced neutralizing antibodies against the Omicron variant BA.1. However, the Sanofi-GSK next-generation candidate produced the highest response, according to data published as a pre-print prior to peer review.

Another late-stage trial involved 1,500 people of those who had previously received an mRNA vaccine, such as the one from Pfizer (PFE) / BioNTech (BNTX) and Moderna (mRNA), indicating that the new vaccine candidate led to a significant increase in antibody levels against some of the variants of interest.

According to initial data, there was a 40-fold increase in antibody titers against variant BA.1 and the new vaccine version doubled the number of neutralizing antibodies against Omicron BA.1 and BA. 2 compared with the original vaccine candidate.

Both studies showed that the experimental vaccine was well tolerated with favorable safety profile. However, the 1,500 . group the subjects in the second test are shown less than 4% of tertiary reactions, according to Sanofi (SNY), is temporary and not serious.

The first recombinant vaccine candidate developed by Sanofi (SNY) and GSK (GSK) is currently under review under European regulation for COVID-19.

Read about the prospect of a Sanofi-GSK vaccine against mRNA vaccines are widely used.